Quantcast
Last updated on April 19, 2014 at 1:20 EDT

Prosonix Appoints Frank Condella as Non-executive Director

July 1, 2013

OXFORD, England, July 1, 2013 /PRNewswire/ –

Brings further international experience in the development and commercialisation of
respiratory medicines

Prosonix, an innovative speciality pharmaceutical company developing a portfolio of
inhaled respiratory medicines by design, has appointed Frank Condella as Non-executive
Director.

Mr Condella has over 30 years of business experience, including senior leadership
roles in both privately and publicly held companies in the pharmaceutical and healthcare
industry, and particularly in the development and commercialisation of respiratory
medicines.

Mr Condella is President and Chief Executive Officer of Columbia Laboratories, Inc., a
NASDAQ-listed speciality pharmaceutical company, and Non-executive Chairman of Skyepharma
plc, a London-listed speciality drug delivery company. He was CEO of Skyepharma between
2006 and 2008, President of European Operations and Managing Director, UK at IVAX
Corporation from 2002 to 2006, and President and Chief Executive Officer of Faulding
Pharmaceutical Co., from 2000 to 2001. Previously, he was Vice-President of Specialty Care
Products at Roche and Vice-President and General Manager of the Lederle unit of American
Home Products (now part of Pfizer, Inc.). He holds a MBA degree and a BSc degree in
pharmacy from Northeastern University (Boston, MA, USA).

Commenting on the appointment, Ken Cunningham, Prosonix’ Non-executive Chairman, said:

“Prosonix has been successful in recruiting people with important and complementary
industry experience to add to its management, board and advisory committee over the past
18 months so as to take full advantage of the commercial opportunity that its generic and
novel respiratory drug candidates have the potential to address. We are therefore very
pleased that Frank has joined the Prosonix Board. We anticipate his wide-ranging
experience in developing and commercialising respiratory and other speciality medicines
will prove valuable as we advance our lead programmes towards the market.”

Frank Condella added:

“Prosonix has developed a unique platform for developing generic and novel respiratory
medicines based on engineering drug particles whose fundamental properties are designed
specifically for inhalation via simple inhalation devices. This approach could lead to the
availability of the first directly substitutable generic respiratory medicines, as well as
novel combination products with enhanced performance and cost benefits. Prosonix is a very
exciting company and I am very much looking forward to working with the company during
this transformational phase of its development.”

Notes for Editors

About Prosonix http://www.prosonix.co.uk

Prosonix is an innovative speciality pharmaceutical company developing a portfolio of
inhaled respiratory medicines by design.

Prosonix’ ultrasonic particle engineering technology enables it to design and engineer
mono and combination drug particles that precisely meet the specific requirements for
inhalation, delivering assured formulation performance using simple, cost-effective
devices for a range of generic, super-generic and novel products.

Prosonix’ pipeline focuses on near- and long-term opportunities, including:

        - PSX1001/PSX1050, a directly substitutable generic version of fluticasone
          propionate, a potent inhaled corticosteroid (ICS) monotherapy, for asthma and chronic
          obstructive pulmonary disease (COPD) in pressurised metered dose inhaler (pMDI),
        - PSX2005, a directly substitutable generic version of a leading ICS/long-acting
          beta agonist (LABA) combination in development for asthma and COPD in pMDI,
        - PSX1002, a drug-only proprietary formulation of glycopyrronium bromide, a
          long-acting muscarinic antagonist (LAMA), for COPD in pMDI, and
        - PSX2000 MCP(TM) Series, novel combination medicines designed specifically for
          respiratory diseases and based on Prosonix proprietary Multi-component Particles(TM)
          that uniquely do not require additional excipients or co-suspension agents for optimal
          formulation performance from pMDI or Dry Powder Inhalers (DPI).

Prosonix has raised more than GBP22 million from experienced life sciences investors
including Ventech, Gimv, Gilde Healthcare Partners, Entrepreneurs Fund, Quest for Growth
and Solon Ventures, plus GBP1.3 million from the Biomedical Catalyst.

        For more information, please contact:

        David Hipkiss, CEO
        +44(0)1865-784-250
        david.hipkiss@prosonix.co.uk

        Mark Swallow, Sita Shah, David Dible
        Citigate Dewe Rogerson
        +44(0)207-638-9571
        prosonix@citigatedr.co.uk

SOURCE Prosonix


Source: PR Newswire